CD274 and cancer: We used tumor-bearing PBL-NOG-hIL-4-Tg humanized mice and found that atezolizumab, an anti-PD-L1 mAb and a derivative cancer drug, are effective against the triple-negative breast cancer cell line MDA-MB-231 in vivo (Kametani, et al., 2023).